Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Subarachnoid haemorrhage
Clinical narrative: headache; nausea; chills; Hemorrhage brain; stroke; subarachnoid hemorrhage; was asleep and not aware of anything for 3 days; This spontaneous case was reported by a consumer and describes the occurrence of CEREBRAL HAEMORRHAGE (Hemorrhage brain), CEREBROVASCULAR ACCIDENT (stroke), SUBARACHNOID HAEMORRHAGE (subarachnoid hemorrhage), HEADACHE (headache), LOSS OF CONSCIOUSNESS (was asleep and not aware of anything for 3 days), NAUSEA (nausea) and CHILLS (chills) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was reported.     On 27-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Jun-2021, the patient experienced CEREBRAL HAEMORRHAGE (Hemorrhage brain) (seriousness criteria hospitalization, medically significant, life threatening and intervention required), CEREBROVASCULAR ACCIDENT (stroke) (seriousness criteria hospitalization, medically significant, life threatening and intervention required) and SUBARACHNOID HAEMORRHAGE (subarachnoid hemorrhage) (seriousness criteria hospitalization, medically significant, life threatening and intervention required). On an unknown date, the patient experienced HEADACHE (headache) (seriousness criteria hospitalization, life threatening and intervention required), LOSS OF CONSCIOUSNESS (was asleep and not aware of anything for 3 days) (seriousness criteria hospitalization, medically significant, life threatening and intervention required), NAUSEA (nausea) (seriousness criteria hospitalization and life threatening) and CHILLS (chills) (seriousness criteria hospitalization and life threatening). The patient was hospitalized on 02-Jun-2021 due to CEREBRAL HAEMORRHAGE, CEREBROVASCULAR ACCIDENT, HEADACHE and SUBARACHNOID HAEMORRHAGE. The patient was treated with PARACETAMOL (TYLENOL) for Headache, at a dose of 1 dosage form. At the time of the report, CEREBRAL HAEMORRHAGE (Hemorrhage brain), CEREBROVASCULAR ACCIDENT (stroke), SUBARACHNOID HAEMORRHAGE (subarachnoid hemorrhage), HEADACHE (headache), LOSS OF CONSCIOUSNESS (was asleep and not aware of anything for 3 days), NAUSEA (nausea) and CHILLS (chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient had brain hemorrhage and stroke. The patient was airlifted to nearby hospital from local hospital spent 8 days in the ICU. It was called subarachnoid hemorrhage. They took patient in ambulance and then they found blood in her brain so they flew her to nearby hospital for neurological ICU did EKG, MRIs and ultrasounds of brain (results were not provided). The patient had no underlying health conditions. After getting the vaccine, patient had the worse headache was screaming.  The headaches very soon after the vaccine and it kept on getting worse and worse. The patient was taking Tylenol but it was not taking the pain away. The patient was asleep and not aware of anything for 3 days and then patient called an ambulance. The patient had nausea and chills was scared to get the second shot. No concomitant medication were provided.  Company Comment: This case concerns a 49-year-old female hospitalized with serious unexpected events of cerebral haemorrhage, cerebrovascular accident, subarachnoid haemorrhage, loss of consciousness, headache, nausea, and chills. Event onset 6 days after second dose mRNA-1273. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Sender's Comments: This case concerns a 49-year-old female hospitalized with serious unexpected events of cerebral haemorrhage, cerebrovascular accident, subarachnoid haemorrhage, loss of consciousness, headache, nausea, and chills. Event onset 6 days after second dose mRNA-1273. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.